OpenCharities

This text was generated using OCR and may contain errors. Check the original PDF to see the document submitted to the regulator.

2026-03-31-accounts

Unlimit Health

Annual Report and Financial Statements for the year ending 31 March 2026

Unlimit Health annual report and financial statements | 1

Contents List of acronyms ................................................................................................................................................. 4 Foreword by the Co-Chairs of the Board of Trustees ........................................................................................ 6 Report of the Trustees ....................................................................................................................................... 6 Our purposes and activities ........................................................................................................................... 8 Public Benefit Statement ............................................................................................................................. 11 Grant Making Policy .................................................................................................................................... 12 Achievements, Performance and Future Plans ........................................................................................... 12 Goal 1: Accelerate programmatic action towards elimination of parasitic infections and health equity. ................................................................................................................................................................. 12 Goal 2: Intensify cross cutting approaches to elimination and health systems strengthening. ............. 19 Goal 3: Promote and enable country ownership and leadership of programmes for elimination of parasitic infections................................................................................................................................... 23 Goal 4: A strong sustainable and flexible organisation providing a working environment which attracts and retains great staff with efficient and adaptive systems and providing a strong accountability to the supporters, partners, and funders. ......................................................................................................... 25 Financial review ........................................................................................................................................... 29 Reserves Policy ............................................................................................................................................ 32 Investment Policy and Performance ........................................................................................................... 33 Principal Risks and Uncertainties ................................................................................................................ 34 Structure, Governance and Management ................................................................................................... 37 Trustees’ responsibilities in relation to the financial statements ............................................................... 39 Reference and Administration Details ............................................................................................................ 41 Independent Auditor’s Report to the members of Unlimit Health. ................................................................ 43 Statement of Financial Activities (incorporating an income and expenditure account) ................................. 47 Balance Sheet (Company Number 11775313) ............................................................................................... 47

Unlimit Health annual report and financial statements 2025-2026 | 2

Statement of Cash Flows ................................................................................................................................. 49 Notes to the financial statements ................................................................................................................... 49

Unlimit Health annual report and financial statements 2025-2026 | 3

List of acronyms

Unlimit Health annual report and financial statements 2025-2026 | 4

Unlimit Health annual report and financial statements 2025-2026 | 5

Foreword by the Co-Chairs of the

Board of Trustees

As Co-Chairs of Unlimit Health, it is our privilege to introduce this Annual Report for the year ended 31 March 2026.

The past year has brought both significant achievement and considerable challenge for global health. Across many endemic countries, communities continue to face the burden of preventable parasitic infections while also navigating wider pressures on health systems, economic uncertainty, conflict, climate-related threats and a rapidly changing international development landscape. At the same time, shifts in global financing have reinforced the importance of resilient, country-owned health systems capable of sustaining progress for the long term.

Against this backdrop, Unlimit Health has remained firmly focused on its mission: sharing evidence and expertise to end preventable parasitic infections in affected communities. We are particularly encouraged that the organisation has continued not only to deliver impact, but to do so with countries, communities and partnerships at the heart of decision-making.

This report demonstrates the scale and significance of that work. During the year, Unlimit Health supported Ministries of Health to deliver more than 27 million treatments for neglected tropical diseases and helped over 16 million people access interventions that protect health, improve wellbeing and expand future opportunities. These achievements matter not simply because of the numbers reached, but because they represent children better able to attend school, women better able to participate fully in society, and communities moving closer to a future free from diseases that have constrained development for generations.

We are especially proud of the organisation's continued commitment to generating and applying high-quality evidence. Through impact assessments, surveillance, operational research and technical partnerships, Unlimit Health is helping countries make informed decisions about where resources should be directed and how interventions can be delivered most effectively. This "precision public health" approach is increasingly important as countries move from disease control towards elimination and need more targeted, data-driven strategies.

Unlimit Health annual report and financial statements 2025-2026 | 6

The year also highlighted the growing importance of integration. The challenges facing communities do not occur in isolation, and neither should the solutions. Unlimit Health has continued to strengthen links between parasite elimination programmes and wider health system priorities, including water, sanitation and hygiene, nutrition, women's health, animal health and primary healthcare services.

During the year, the Board undertook a comprehensive mid-term review of the organisation's strategy. This process confirmed both the continuing relevance of Unlimit Health's mission and the value of its distinctive role in global health. We were encouraged by the confidence expressed by partners and stakeholders, and by the clear evidence that the organisation is making a meaningful contribution to the goals set out in the WHO Neglected Tropical Diseases Road Map to 2030. Following the review, the Board approved an extension of the strategic timeframe to 2030, ensuring continued alignment with global ambitions while retaining the flexibility to respond to emerging opportunities and challenges.

None of this progress would be possible without the dedication and professionalism of Unlimit Health's staff, the commitment of our partners, the leadership of Ministries of Health, the support of our funders and, above all, the trust and engagement of the communities with whom we work. We extend our sincere thanks to every one of them.

We commend this report to you and thank all those who continue to share and support Unlimit Health's vision of resilient systems that sustain good health, so that everyone, everywhere, can reach their full potential.

Dr Camilla Ducker & Professor Samba Sow Co-Chairs of the Board of Trustees

Unlimit Health annual report and financial statements 2025-2026 | 7

Report of the Trustees

The Trustees present their report, incorporating the requirements of a strategic report, together with the financial statements of Unlimit Health for the year ended 31 March 2026. The report has been prepared in accordance with Part VIII of the Charities Act 2011 and constitutes a directors’ report for the purposes of company legislation.

The financial statements and notes have been prepared in accordance with the accounting policies and comply with the charitable company’s Memorandum and Articles of Association, applicable laws, the Companies Act 2006 and Accounting and Reporting by Charities: Statement of Recommended Practice, applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the United Kingdom and Republic of Ireland (FRS 102).

Our purposes and activities

Unlimit Health purpose

The objects of the Charity are, for the public benefit:

  1. To promote the physical and mental health of people and communities in any part of the world who are affected by neglected tropical diseases as defined by the World Health Organization including, but not limited to, parasitic worm infections, schistosomiasis and soil-transmitted helminthiasis (collectively “neglected tropical diseases”).

  2. To relieve the needs of people and communities in any part of the world who are suffering as a consequence of neglected tropical diseases; and

  3. To advance the education of people and communities in any part of the world who are affected by neglected tropical diseases and the public with a view to reducing transmission and infection.

By:

Unlimit Health annual report and financial statements 2025-2026 | 8

Our goals under our strategy 2023-2028

Our vision is ‘Resilient systems that sustain good health, so everyone everywhere can

reach their full potential.’

Our mission: We share evidence and expertise to end preventable parasitic infections in

affected communities.

To achieve the goals outlined in our five-year strategy, we have undergone several significant strategic and operational shifts. The strategy therefore included two transitional objectives to support the longer-term achievement of our strategic goals:

  1. Develop a ‘precision public health for parasitic infections’ technical approach

  2. Develop a health systems strengthening technical approach

Over this reporting period, we have incorporated the activities required to fulfil these transitional objectives into our broader operational plan; consequently, this report will not include specific reporting against these objectives. Detail on the transitional objectives was included in our previous annual report. During the year, and based on the outputs for the Mid -term strategy review the Board approved an operational and financial plan covering the period 2026-2030, that extended the 2023-2028 strategy out to 2030. The activities, performance and achievements reported within these financial statements relate to the 2023-2028 strategy, under which they were delivered. References to the 2026-2030 strategy are

Unlimit Health annual report and financial statements 2025-2026 | 9

included where relevant to reflect the Charity’s future strategic direction and priorities, which will guide activities and reporting in subsequent financial periods.

Enablers to reaching our goals

To fulfil our mission, we work in partnership to develop country-owned solutions that eliminate parasitic infections, for good. This involves delivering services under three key areas:

Unlimit Health annual report and financial statements 2025-2026 | 10

Our Values

We are a team of people passionate about creating a world free of preventable disease. It is important that everyone that works at Unlimit Health, as well as our partners and supporters, share the same values and beliefs:

Priorities set for the Reporting Period 2025-2026

During this reporting period, our priorities remained focused on providing technical expertise to countries across a range of thematic areas, notably generating data to inform decision-making, refining strategies through an evidence-based approach, monitoring progress against global and national goals, and supporting effective cross-sectoral engagement.

The process was led by the Co-Chairs and Trustees, working closely with the leadership team. It drew on a wide range of evidence, including progress against strategic goals, operational plans, financial and governance reporting, and reflections on changes in the wider global health ecosystem. Trustees provided both challenge and support, expressing strong confidence in the leadership team and staff, and affirming that Unlimit Health is uniquely positioned to contribute to the elimination of schistosomiasis through its integrated, country-driven and partnership-based approach.

The review confirmed the increasing relevance of the organisation’s strategic direction in the current global climate while also identifying areas for sharper focus to ensure that Unlimit Health continues to work collaboratively, responsibly and with clear strategic intent. The Board also approved the extension of the strategic period to 2030 to further align with the WHO Road Map 2021 -2030 suggesting a further review in 2028 in preparation for a new strategy post 2030.

Unlimit Health annual report and financial statements 2025-2026 | 11

Public Benefit Statement

The Trustees confirm that they have had regard to the Charity Commission’s guidance on public benefit and the ways in which Unlimit Health delivers public benefit are explained in reporting on the Charity’s Achievements, Performance and Future Plans.

Grant Making Policy

Unlimit Health partners primarily with Ministries of Health to support the delivery of public health interventions in sub-Saharan Africa. Unlimit Health works with its partners to develop programmes and determine the financial support required. Annual contracts document the programmes and financial support to be provided. The financial support is referred to as partner awards or payments in the annual report.

Achievements, Performance and Future Plans

Goal 1: Accelerate programmatic action towards elimination of parasitic infections and health equity.

Objectives:

1. Be an effective technical partner in the innovation, design and delivery of interventions for all inneed groups.

2. Enhance technical support to innovate and embed monitoring, evaluation and surveillance tools and strategies for elimination.

Key Achievements:

Unlimit Health annual report and financial statements 2025-2026 | 12

ESPEN (Expanded Special Project for Elimination of NTDs) Portal). This has helped strengthen collaboration with ESPEN on the improvement of treatment planning tools such as the Community Data Workbooks (CDW) alongside supporting their data work on administrative units. In December 2025, we joined the Regional Workshop on Data Systems, Tools and Processes for PC-NTDs convened by ESPEN which was critical for the alignment of data capture, interpretation and decision-making to better target resources for schistosomiasis control and elimination.

Additional SNAPS outputs that have been developed and will be delivered by Q1 2026/27 include: a systematic review on the impact of interventions for the control and elimination of SCH; an investment case for impact assessment; a Monitoring, Evaluation and Learning Resource Hub; and case-study country summaries describing the impact of treatment over time, developed in partnership with the Global Geostats Hub at the University of Birmingham.

o Unlimit Health continued collaboration on the END Fund’s Deworming and Innovation Fund which included supporting writing and submission of both UH and country-led publications related to the project as well as the development of a Stop MDA Survey design. The following manuscripts were submitted and are under review (several have been resubmitted following reviewers’ comments)

(i) Burden of schistosomiasis in Ethiopia following ten years of preventive chemotherapy: a national cross-sectional geostatistical survey at The Lancet Global Health – (preprint https://dx.doi.org/10.2139/ssrn.6134853)

(ii) A national geostatistical survey for schistosomiasis and soil-transmitted helminths in Zimbabwe following interruption of preventive chemotherapy Short Title: Geostatistical impact assessment of helminth infections in Zimbabwe at BMC Public and Global Health

(iii) Applying geostatistical approaches to programmatic decision-making in schistosomiasis and soil-transmitted helminthiasis at International Health

Unlimit Health annual report and financial statements 2025-2026 | 14

(iv) From district to community: fine-scale data and revised WHO guidance expand schistosomiasis treatment needs in Ethiopia and Zimbabwe at PLoS NTDs (preprint https://doi.org/10.64898/2026.04.07.26350372)

Unlimit Health annual report and financial statements 2025-2026 | 15

survey in three districts in 2022. Parasit Vectors . 2026 https://doi.org/10.1186/s13071-02607357-6

Unlimit Health annual report and financial statements 2025-2026 | 16

advocacy and funding; and capacity and awareness building. This consultation follows up on a similar project conducted during 2023-2024, which focused on four different themes: diagnostics, M&E, access and logistics, and advocacy and funding. Final results will finish the updating of the roadmap for all NTDs and dimensions. To this effect, twenty-two disease-specific focus group discussions (FGDs) are planned to take place with disease experts, WHO officials and programme managers across April - June 2026. Subsequently, UH will further conduct dimension-level FGDs, focusing on developing crosscutting recommendations across multiple NTDs, particularly related to mainstreaming, integration, and inter-sectoral coordination. The latter discussions are expected to be completed by July 2026. A report, with detailed narrative synthesis and programmatic recommendations at disease- and dimensionlevels, is expected to be produced by August 2026 and included in a WHO publication reporting on their mid-term review for this decade. A comprehensive final report will be submitted to the Strategic and Technical Advisory Group for Neglected Tropical Diseases for approval and endorsement during AugustSeptember 2026.

Unlimit Health annual report and financial statements 2025-2026 | 17

country contexts. The guide will be submitted to EDCTP as a major project deliverable and subsequently disseminated to Ministries of Health and implementing partners with an interest in integrating the new treatment into child health and/or NTD services.

Plans for the Next Period

Unlimit Health’s continued approach of working directly with Ministries of Health to support public health interventions leading to the longer-term gains in eliminating SCH and STH as a public health problem has put the organisation in a very strong position to support the development of resilient health systems that provide health care for all, as outlined in the Sustainable Development Goals and the Universal Health Coverage agenda. As such, Unlimit Health will continue to:

Unlimit Health annual report and financial statements 2025-2026 | 18

Goal 2: Intensify cross cutting approaches to elimination and health systems strengthening.

Objectives:

  1. Enhance integration and mainstreaming of elimination interventions and care into appropriate delivery platforms and routine health service delivery and information systems.

  2. Support cross sectoral coordination and action at sub national, national, and international levels.

Key Achievements:

Unlimit Health annual report and financial statements 2025-2026 | 19

Unlimit Health annual report and financial statements 2025-2026 | 20

Health secured funding from Merck, The END Fund and the Gates Foundation to evaluate this approach, comprising monitoring distribution, evaluating the process, as well as assessing coverage and policy aspects of integration.

Results from M&E activities were promising and the process evaluation found that planning, training, sensitisation, and drug delivery activities largely followed established processes and protocols with key challenges identified. The policy assessment also highlighted further areas for ongoing optimisation. UH continues working with the MoH to support integrated treatment initiatives.

NTD and WASH teams to publish “Delivering a shared vision: Lessons and gaps following a decade of joint action on WASH and NTDs”, a report on progress since 2015 in implementing the Global Strategy on WASH and NTDs.

Unlimit Health annual report and financial statements 2025-2026 | 21

FCDO) through chairing of roundtables pre- and post- international WHO negotiation sessions.

Chaired the NNN One Health working group, including running a conference workshop with a community focus and generating case study videos from NTD endemic countries.

Unlimit Health continued to deepen its advocacy partnership with the nutrition sector to influence advocacy and engagement on parasitic infections and nutrition, including strengthened relationships with the nutrition team at FCDO; Led the development of wider health policy positioning recommendations to FCDO after the N4G Summit which led to a joint CEO meeting with FCDO Minister of State Baroness Chapman in June 2025. Unlimit Health CEO led health integration interventions during the meeting. https://www.actionagainsthunger.org.uk/wp-content/uploads/2025/01/ICAN-UK-recommendationsto-the-FCDO-for-N4G-2025.pdf

Supported the parliamentary reception hosted by the APPG on Nutrition for All in March 2026 and attended by the FCDO Parliamentary Under-Secretary of State, Chris Elmore MP; to strengthened connections and networking opportunities between Unlimit and key stakeholders to build upon to advance Unlimit Health’s work on nutrition and health integration.

Plans for the Next Period

In 2026-27, we will

Unlimit Health annual report and financial statements 2025-2026 | 22

Goal 3: Promote and enable country ownership and leadership of programmes for elimination of parasitic infections.

Objectives:

  1. Support country system governance, readiness, and expertise.

  2. Catalyse resource mobilisation aligned with country plans and mechanisms.

Key Achievements:

o Sustainable resourcing :

o One Health Systems Strengthening in Zanzibar:

Unlimit Health annual report and financial statements 2025-2026 | 23

Plans for the Next Period

In 2026-27, we will continue to embed efforts and initiatives in support of country ownership in our own work and in the broader NTD and global health community. This will include, among other activities:

Unlimit Health annual report and financial statements 2025-2026 | 24

Goal 4: A strong sustainable and flexible organisation providing a working environment which attracts and retains great staff with efficient and adaptive systems and providing a strong accountability to the supporters, partners, and funders.

Objectives:

  1. Ensure transparency and accountable finance and resource management systems are in place compliant with all relevant regulations including the Charity SORP. Ensure robust internal controls are in place.

  2. Build a sustainable funding base for the organisation and provide stewardship for all funders.

  3. Build and maintain a working environment that attracts and retains great people, with a thriving, value-led culture, where our people feel valued, are appropriately compensated and equipped with tools to do their job and can bring their whole selves to work to achieve results that deliver the strategy.

  4. Ensure that we have a robust Safeguarding process in place that is clear, accessible and embedded throughout organisation and that is regularly reviewed at Board level.

  5. Ensure effective, values-driven, and impactful external communications, in support of the organisational vision and strategy.

Key Achievements:

The strategy continues to be warmly received by stakeholders including funders, Ministry of Health colleagues from endemic countries, and other agencies. Unlimit Health has two Co-Chairs with one Co-chair from an endemic country.

Unlimit Health annual report and financial statements 2025-2026 | 25

Unlimit Health continued work as a key member of the Action for Global Health network, inputting in the network’s theory of change and advocacy plans. Unlimit Health’s Senior Advocacy Advisor coleads the Parliamentary Influencing Group.

Unlimit Health annual report and financial statements 2025-2026 | 26

Unlimit Health annual report and financial statements 2025-2026 | 27

Plans for the Next Period

We will continue to be responsive to the changing global health landscape in which Unlimit Health operates, ensuring that our strategic direction remains aligned, and our operations remain fit-for-purpose whilst maximising efficiency and effectiveness. We will maintain a values-driven culture to ensure that our leadership and management remains equitable, transparent and inclusive. This is particularly important given the instability of the global economy and the impacts of International Development Aid.

Support the influencing of global health and development policy and developing strategic partnerships, in support of efforts to eliminate parasitic disease. Including: Ongoing policy and advocacy action and network engagement; Exploring the links between Unlimit Health's One Health system strengthening and gender, climate change, pandemic PPR and AMR agendas; and advocating for sustainable financing at national and international levels, advancing One Health prioritisation and embedding in UKG departments and international agreements or bodies. This will include engaging with the Global Partnerships Conference in London in May 2026 hosted by the UK Government, South Africa, Children’s Investment Foundation Fund and British International Investment, as well as preparations to advance policy advocacy efforts targeting the G20 Summit in 2027 under the UK presidency.

Unlimit Health will provide transformative thought leadership as Vice-Chair and Chair of the NNN, guiding the development of a renewed collective identity and forward-looking strategic framework aligned with the 2030 NTD roadmap. This leadership role positions Unlimit Health at the forefront of shaping the future landscape of global NTD collaboration, strengthening our influence in policy development and implementation while establishing innovative governance models that enhance the network's effectiveness and sustainability.

Unlimit Health annual report and financial statements 2025-2026 | 28

Financial review

We have realised a deficit of £3.12m (2025: £1.95m deficit), which was in line with our Operational Plan. This means that Unlimit Health held total funds of £8.98m (2025: £12.11m) at year-end. These funds are made up of restricted funds of £0.23m (2025: £0.30m), unrestricted general funds of £4.83m (2025: £7.25m), and designated funds of £3.92m (2025: £4.55m) which the trustees have earmarked, and we will draw down over the next two years to fund specific programme charitable activities as outlined in the Operational Plan.

Unlimit Health received a total income of £5.85m (2025: £6.80m), the overall decrease relating almost exclusively to a reduction in recognised Grant income. The income on some grants received in advance could only be recognised upon performance in accordance with the donor’s wishes. Some of our Ministry of Health partners continued to experience delays with the arrival of donated drugs which prevented MDAs from proceeding as planned, and so Unlimit Health could not spend in the country and recognise the corresponding income. These delayed activities will be carried out in the next financial year and therefore the corresponding income recognised also in the next financial year. We were not able to do any work in Sudan this year, but work is planned for the next financial year.

Donations and legacies increased slightly from £1.32m to £1.33m. The Investment income continued to perform well, although investment valuations reduced significantly at year end due to the crisis in the Gulf. Almost all of these losses were reversed in the first month of the year.

Unlimit Health spent £8.88m over the year (2025: £8.82m). There was a slight increase in expenditure and we would have spent more in the year in line with the structured drawdown of the designated funds had the various Ministry of Health partners received their drug donations from WHO on time, but we could not implement the planned level of activities in Sudan or Burundi. UH has reported supporting the delivery of 27 million treatments in the reporting period. As detailed above (Goal 1 Key Achievements) several treatment campaigns are still ongoing or delayed and therefore treatment numbers are yet to be finalised. We would have reported higher expenditures by partners had MDA campaigns been implemented as planned.

The financial year has ended with a strong balance sheet. At the year end, cash and cash equivalents were £6.33m (2025: £6.63m). Long- and short-term investments were £6.31m (2025: £11.41m), the reduction being a planned divestment to fund ongoing charitable activities. The total creditors balance at the end of the financial year was £4.17m (2025: £6.37m), the reduction representing the recognition of deferred income in the year which at year end was £3.71m (2025: £5.98m). All of the deferred income (2025: £2.77m) is earmarked by the funders for expenditure in the next financial year.

Unlimit Health annual report and financial statements 2025-2026 | 29

Income Generation

Overall income from donations was slightly above the previous year whilst institutional income was significantly lower leading to total income of £5.85m (2025: £6.80m). Higher income from Effective Altruism organisations and major donors offset a reduction in individual donors and trusts and foundations.

Individual giving

Income from individuals, including major donors, was 11% higher at £0.59m (£0.53m, 2025). This result is due to the acquisition of new major donors whilst maintaining the interest of established donors with faceto-face meetings and increased opportunities for matched giving.

This year we stabilised the decline in individual donor numbers. Our successful public fundraising including matched funding campaigns in July and December 2025 raised over £200,000.

Effective Altruism

EA income was 9% higher than in 2025. We have deepened our relationships with key EA organisations this year, including The Life You Can Save, R C Forward (Canada) and Founders Pledge, and we secured a crucial emergency grant from the Life You Can Save to ensure continuity in Niger’s MDA programme. We have a new donor partnership in EA Hong Kong.

Trusts and Foundations and Institutional funders

Total Institutional income was significantly lower at £2.97m (£5.28m, 2025) reflecting the difficult funding environment, phasing down of the Give Well programme, delays to in country programming with some ministry partners on some existing agreements and significantly lower levels of new approvals across the portfolio. Trusts and Foundations income from small and medium-sized trusts was lower to prior year at £123,500.

Fundraising plans

Our ambition in 2026/2027 is to increase income across all four streams from individuals, major donors, Effective Altruism and trusts and foundations. The strategies we will use include a strong emphasis on engaging existing and new potential donor audiences with our high-impact programmes. We will be investing in identifying and acquiring new individual donors and nurturing our existing fantastic

Unlimit Health annual report and financial statements 2025-2026 | 30

supporters. We are developing a pipeline of new trust and foundation relationships. We are confident that support for highly cost-effective disease-elimination programmes will continue to attract significant backing from the EA community. We expect to see an increase in income in 26/27 and beyond.

Whilst the recent and ongoing cuts in Official Development Assistance (ODA) budgets in the US, UK, Germany, France, Netherlands, and Sweden are impacting ODA levels significantly, there are opportunities especially in research funding, health integration and health system strengthening. The significantly lower levels of ODA funding for global health is catalysing new thinking around national domestic resource mobilisation and increasing the effectiveness of treatment and prevention programmes. We will continue to engage with multi- and bilateral funding institutions to ensure that, where possible, sufficient resources are available to support the elimination of preventable parasitic disease. Private sources of philanthropy have a key role in catalysing and leveraging new funding and financing as official funding is reduced. We will continue to solicit support for our elimination agenda from all our donors and aim to increase our approaches to sources of sustainable restricted funding.

Disclosure under The Charities (Protection and Social Investment) Act 2016

Unlimit Health annual report and financial statements 2025-2026 | 31

Reserves Policy

Unlimit Health’s mission is to support the development of effective and sustainable systems that will eliminate parasitic worm infections. The public health interventions required to reach elimination, including treatment of at-risk populations, require sustained implementation over multiple years. The current World Health Organisation guidance recommends an initial 5-6 years of annual treatment before reassessment.

Unlimit Health maintains reserves to allow the Charity to continue to fulfil its objectives and withstand any period of financial uncertainty. Unlimit Health normally has two types of reserves:

The Trustees set a target level for unrestricted General Funds which the Charity aims to hold over the medium term for the above purposes. Such funds provide a measure of financial stability to the Charity and thereby reinforce the reputation and ability of the Charity to deliver on promises.

Each year the minimum level of unrestricted General Funds is reviewed by the Trustees, and consideration is given to the following when deciding the level of funds required:

Unlimit Health annual report and financial statements 2025-2026 | 32

After careful assessment of the above, and in line with good governance practice, the Trustees have reviewed all identified risks and have concluded that the minimum level of Free Reserves (General Funds less Tangible Fixed Assets) should be maintained at a level that is higher than the cost of an orderly closure of the Charity and falls between three- and four-months’ worth of unrestricted expenditure budget for the following financial year (between £1.2m and £1.6m ). The cost for an orderly closure is £1.79m. The costs for an orderly closure is higher than three- and four-months’ worth of unrestricted expenditure budget for the following financial year. The free reserve level for 2025/26 should therefore be £1.79m .

The Free Reserves as of 31 March 2026 totalled £4.82m which is £3.03m above the higher Reserve Policy level. There is a clear plan in place, and the Trustees expect that there will be a structured draw down of the reserves to invest in programmes, programme development and our funding model as outlined in the 2026-2030 Strategic Plan . The reserve level will continue to decrease in the coming years and will be in line our Reserve Policy.

Investment Policy

The Board of Trustees of Unlimit Health has delegated investment decisions to the Finance, Risk and Audit committee. We have recruited CCLA Fund Managers, who are regulated by the FCA, to manage our longterm investments.

The objectives and policies of Unlimit Health investments are:

Unlimit Health has adopted an ethical investment policy to ensure that its investments do not conflict with its aims. Excluded are activities that have a direct impact on health e.g., tobacco and alcohol. Activities that have a direct impact on the environment e.g., illegal logging, and activities that undermine human rights, e.g. sexual misconduct.

Unlimit Health annual report and financial statements 2025-2026 | 33

Investment Performance

CCLA Fund Managers manage two COIF Charity Funds' portfolios for Unlimit Health: The Ethical Investments and Short Duration Funds. Over the year, the portfolio realised a Total Return Performance of +2.4% (2024-25: +8.7%) compared to the +3.0% (2024-25: +3.4%) for the Consumer Price Index.

The Ethical Funds significantly underperformed, realising a capital loss of £237,681 (2024-25: £301,830 gain). The Fixed Interest portfolio performed better this year and realised capital growth of £142,898 (2024-25: £337,599 gain).

Fund performance is shown after the deduction of all fees and expenses with income reinvested. Comparator returns are based on market indices which are not adjusted for management fees or expenses.

The Ethical Investment funds total return performance over 12 months to 31 March 2026 was -6.17% against +13.14% for the Fund Comparator (2024-25: +13.11% against +16.72% for the Fund Comparator). The fund therefore underperformed the fund comparator this year. The Ethical Fund has underperformed the Fund Comparator over both three- and five-year averages.

The Short Duration funds total return performance over 12 months to 31 March 2026 was +4.71% against +5.92% for the Fund Benchmark (2024-25: +6.91% against +6.76% for the Fund Benchmark). The Fixed Interest funds performed worse than the Fund Benchmark this year, as well as the three- and five-year averages. The board have agreed a managed divestment plan for both the Ethical and Short Duration Funds which will continue to be reviewed throughout the 2026-27 financial year.

Principal Risks and Uncertainties

Risk management is central to the ability of Unlimit Health to deliver its objectives. We use multiple ways of managing risks through the Leadership Team (LT), Technical Team, the Finance Risk & Audit Committee (FRAC) sub-committee to the Board, and the Board. Central to this is a rigorous budget process with appropriate internal controls including only spending secured funds, with projects planned to optimise cash flow and value for money.

The LT meets regularly and monitors and reviews key risks. The Technical Team reviews programme risks weekly on a country-by-country basis as part of its routine programme monitoring activities. Discussions are held on monthly management accounts, quarterly re-forecasts, and formal reviews, that are then

Unlimit Health annual report and financial statements 2025-2026 | 34

presented to the Board. These regular reviews ensure that ongoing expenditures align with Unlimit Health’s financial performance targets. In addition, actions taken in response to any issues raised during specific partner assessment or other review activities are implemented in other contexts if applicable.

The FRAC reviews risks, challenges and key financial management policies and assumptions on a quarterly basis. It ensures that the annual operational plan is adequately funded and makes recommendations to the Board for adoption. The LT interacts with the FRAC and implements the scheme of delegation on issues that need reporting to the FRAC.

The Board leads on the review and approval of the Risk Register. This helps Unlimit Health to identify and assess potential risks, and to develop effective mitigation strategies to ensure the needs of communities at risk of NTDs continue to be met.

Unlimit Health has identified the following key risks during the reporting period in the table below.

Major Risk Identified Mitigation
1 International Aid financing
Closure of USAID (20 January 2025) and significant
cuts to UKAid announced (9 April 2025) has
impacted the NTD sector significantly. Although
Unlimit Health did not receive USAID or UKAID funds
directly there are significant impacts in terms of
collaborations and dependent partnerships as well
as broader impacts on the future of international aid
funding.
The Board has continued to convene regularly, with a
diverse membership and extensive expertise in
fundraising and communications to support the
Unlimit Health Team. We engage with a range of
networks and stakeholder groups to ensure that we
contribute appropriately to the advocacy efforts and
identify possible mitigations.
2 Assurances of expenditure by endemic country programmes
To align with the values of the organisation and for
the achievement of the specific objectives of
strategic Goal 3, Unlimit Health supports the
ministries of health to be accountable for NTD
programme expenditure. The need to balance this
with the ability to demonstrate appropriate levels of
financial oversight to funders and fulfil other
regulatory requirements creates challenges and risks
to Unlimit Health.
Unlimit Health has worked with the FRAC and third-
party audit partners to further develop an internal
partnership assessment approach that satisfies
compliance requirements and continues to work
with Ministry of Health colleagues to further
developed the financial management and reporting
accountabilities required, alongside regular
programme audits.

Unlimit Health annual report and financial statements 2025-2026 | 35

3 Sustainability of the supply of Praziquantel

Global crises and financial instability have created uncertainty in global pharmaceutical market making the long-term donation of Praziquantel by Merck KGAa less certain. This in conjunction with demand side issues due to the reduction in distribution funds, reducing the requests received by the WHO from Ministries of Health for Praziquantel has further compounded the challenge.

Unlimit Health has over many years developed strong relationships at all levels within Merck KGAa and is continuing discussions to determine how to advocate most effectively for the continuation of the donation programme in the long term. UH is also engaging with other stakeholders to generate the appropriate data to ensure accurate allocation and utilisation of donated drugs.

Unlimit Health annual report and financial statements 2025-2026 | 36

Structure, Governance and Management

Unlimit Health was incorporated as a Company Limited by Guarantee on 17 January 2019. It was registered as a Charity (standard registration) governed by its Articles of Association by The Charity Commission on 21 February 2019. Previous to this, the SCI Foundation team existed as a unit within the Department of Disease Epidemiology at the School of Public Health, Imperial College London since 2002. Unlimit Health is a charity registered in England and Wales (1182166) and is regulated by the Charity Commission. In March 2023, the name of the Charity was changed to Unlimit Health from SCI Foundation and Companies House and the Charity Commission were informed.

Unlimit Health has a Board of Trustees committed to maintaining a high standard of governance. All Trustees are non-executive, are drawn from diverse, international backgrounds, and bring a broad range of relevant experience and skills. New trustees are appointed through an open and transparent recruitment process and an assessment of the needs of the organisation set out in a skills matrix. Trustees normally serve two terms of three years, although this can be extended under exceptional circumstances (such as where a skill cannot easily be replaced). The Unlimit Health board membership spans several countries, including Canada, Ghana, Mali, the US and the UK, bringing important global perspectives as well as health system expertise from the African region into deliberations. Board member expertise includes journalism, strategic communications, financial services, health programme development, medical practice, research, and technology, across the NGO, private and public sectors. The co-chair of the Board, Professor Samba Sow, previously served as Mali’s Minister of Health and Public Hygiene, and is the current Director General of the Center for Vaccine Development in Mali (CVD-Mali). We have made Board of Trustee meetings more accessible by having three online and one in-person meetings.

Training of Trustees

Trustees are recruited for their specific skills and experience to meet organisational priorities and ensure a wide range of specialist areas. Training for Trustees is conducted in two ways:

  1. Trustees Induction: Each Trustee, following appointment, has an induction meeting with the Chair and the Chief Executive.

2. Safeguarding training: All Trustees are given induction on safeguarding, and one Trustee is nominated as a Safeguarding Trustee. The Safeguarding Trustee has oversight of and ultimate responsibility for a comprehensive set of policies, reporting processes and the organisation’s training plans that are led

Unlimit Health annual report and financial statements 2025-2026 | 37

through the Finance and Operations Team. The Safeguarding Trustee works with the organisation’s CoLead Safeguarding Officers on both the ongoing Safeguarding processes and any incidents as they arise .

Performance of the Trustees both collectively and as individuals is periodically assessed, typically every two years, by an external agency.

With a small, focused Board of Trustees, most of the responsibilities of the Board are discharged by the whole Board, with standing items including:

The Board of Trustees also has separate committees:

The Board of Trustees delegates the responsibility for the day-to-day management of Unlimit Health to the Leadership Team (LT). Policy, strategic and implementation plans are prepared by senior management for consideration and approval by the Board of Trustees. The Leadership Team is comprised of the Directors of the five main functions:

Unlimit Health annual report and financial statements 2025-2026 | 38

Remuneration

Unlimit Health’s policy on remuneration is to ensure that the reward package offered to staff is competitive with other organisations in the international health and development field, to ensure that the organisation is able to recruit and retain high quality staff.

Remuneration is considered by a standing Board of Trustees committee, and in line with the Pay Policy, Unlimit Health also takes advice from an external human resources agency. The salary of the CEO is approved by the Board of Trustees, and the CEO makes recommendations to the Board of Trustees with regards to the salaries of the Key Management Personnel (KMP).

The KMP is composed of the CEO, Executive Director, Director of Research & Innovation, Director of Funding & Communications, Director of Policy and Innovation, and Director of Finance.

As of March 2026, the total employment cost of the KMP was £644k (2025: £604k). The pension cost for the KMP was £32k (2025: £33k). The employment cost increase was due to cost-of-living awards.

All UK staff are paid at least the London living wage.

Trustees’ responsibilities in relation to the financial statements

The Trustees (who are also directors of Unlimit Health for the purposes of company law) are responsible for preparing the Trustees’ Report and the financial statements in accordance with applicable law and United Kingdom Accounting Standards (United Kingdom Generally Accepted Accounting Practice). Company law requires the Trustees to prepare financial statements for each financial year, which give a true and fair view of the state of affairs of the charitable company and of the incoming resources and application of resources, including the income or expenditure, of the charitable company for that period. In preparing these financial statements, the trustees are required to:

The Trustees are responsible for keeping adequate accounting records that disclose with reasonable accuracy at any time the financial position of the charitable company and enable them to ensure that the

Unlimit Health annual report and financial statements 2025-2026 | 39

financial statements comply with the Companies Act 2006. They are also responsible for safeguarding the assets of the charitable company and hence for taking reasonable steps for the prevention and detection of fraud and other irregularities.

The Trustees are responsible for the maintenance and the integrity of the corporate and financial information included on the charitable company’s website. Legislation in the United Kingdom governing the preparation and dissemination of financial statements may differ from legislation in other jurisdictions. In so far as the Trustees are aware:

Signed on behalf of the Trustees

Dr Camilla L Ducker

Co- Chair of the Board of Trustees

Approved on 2[nd] September 2026

Unlimit Health annual report and financial statements 2025-2026 | 40

Reference and Administration

Details

Charity Registration Number: 1182166 Company Registration Number: 11775313 Registered Address and Principal Office: Edinburgh House, 170 Kennington Lane, London, SE11 5DP Trustees: Dr Camilla L. Ducker - Co-Chair Professor Samba O. Sow - Co-Chair Mr Jonathan C. Gorrie - Treasurer Kathryn E. Ager (resigned 20/11/2025) Arielle Dolegui Maxmillian P. Seunik Abena Y. Afari Carolynne M. Wheeler Emily C. Wainwright (appointed 02/02/2026) Chief Executive Officer: Dr Wendy Harrison Key Management Personnel: Dr Wendy Harrison - Chief Executive Officer Dr Lynsey Blair – Executive Director Dr Fiona Fleming – Director of Research and Innovation Mr Dominic Brain – Director of Funding and Communications Mr Gary Hughes – Director of Finance Ms Yael Velleman - Director of Policy and Innovation Auditors: HaysMac LLP, Chartered Accountants, 10 Queen Street Place, London EC4R 1AG

Unlimit Health annual report and financial statements 2025-2026 | 41

Bankers: Barclays Bank, 1 Churchill Place, London E14 5HP Solicitors: Russell-Cooke LLP, 2 Putney Hill, London SW15 6AB Investment Managers: CCLA Fund Managers, One Angel Lane, London EC4R 3AB

Unlimit Health annual report and financial statements 2025-2026 | 42

Independent Auditor’s Report to

the members of Unlimit Health

Opinion

We have audited the financial statements of Unlimit Health for the year ended 31 March 2026 which comprise the Statement of Financial Activities, the Balance Sheet, the Statement of Cash Flow, and notes to the financial statements, including a summary of significant accounting policies. The financial reporting framework that has been applied in their preparation is applicable law and United Kingdom Accounting Standards, including Financial Reporting Standard 102 The Financial Reporting Standard applicable in the UK and Republic of Ireland (United Kingdom Generally Accepted Accounting Practice).

In our opinion, the financial statements:

Basis for opinion

We conducted our audit in accordance with International Standards on Auditing (UK) (ISAs (UK)) and applicable law. Our responsibilities under those standards are further described in the Auditor’s responsibilities for the audit of the financial statements section of our report. We are independent of the Charity in accordance with the ethical requirements that are relevant to our audit of the financial statements in the UK, including the FRC’s Ethical Standard, and we have fulfilled our other ethical responsibilities in accordance with these requirements. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.

Conclusions relating to going concern

In auditing the financial statements, we have concluded that the trustees’ use of the going concern basis of accounting in the preparation of the financial statements is appropriate.

Based on the work we have performed, we have not identified any material uncertainties relating to events or conditions that, individually or collectively, may cast significant doubt on the charitable company's ability

Unlimit Health annual report and financial statements 2025-2026 | 43

to continue as a going concern for a period of at least twelve months from when the financial statements are authorised for issue.

Our responsibilities and the responsibilities of the trustees with respect to going concern are described in the relevant sections of this report.

Other information

The trustees are responsible for the other information. The other information comprises the information included in the Trustees’ Annual Report and the Interim Chair’s Foreword. Our opinion on the financial statements does not cover the other information and, except to the extent otherwise explicitly stated in our report, we do not express any form of assurance conclusion thereon.

In connection with our audit of the financial statements, our responsibility is to read the other information and, in doing so, consider whether the other information is materially inconsistent with the financial statements, or our knowledge obtained in the audit or otherwise appears to be materially misstated. If we identify such material inconsistencies or apparent material misstatements, we are required to determine whether there is a material misstatement in the financial statements or a material misstatement of the other information. If, based on the work we have performed, we conclude that there is a material misstatement of this other information, we are required to report that fact. We have nothing to report in this regard.

Opinions on other matters prescribed by the Companies Act 2006

In our opinion, based on the work undertaken in the course of the audit:

Matters on which we are required to report by exception

In the light of the knowledge and understanding of the charitable company and its environment obtained in the course of the audit, we have not identified material misstatements in the Trustees’ Annual Report (which incorporates the strategic report and the directors’ report).

We have nothing to report in respect of the following matters in relation to which the Companies Act 2006 requires us to report to you if, in our opinion:

Unlimit Health annual report and financial statements 2025-2026 | 44

Responsibilities of trustees for the financial statements

As explained more fully in the trustees’ responsibilities statement set out on page 31, the trustees (who are also the directors of the charitable company for the purposes of company law) are responsible for the preparation of the financial statements and for being satisfied that they give a true and fair view, and for such internal control as the trustees determine is necessary to enable the preparation of financial statements that are free from material misstatement, whether due to fraud or error.

In preparing the financial statements, the trustees are responsible for assessing the charitable company’s ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the trustees either intend to liquidate the charitable company or to cease operations, or have no realistic alternative but to do so.

Auditor’s responsibilities for the audit of the financial statements

Our objectives are to obtain reasonable assurance about whether the financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor’s report that includes our opinion. Reasonable assurance is a high level of assurance but is not a guarantee that an audit conducted in accordance with ISAs (UK) will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these financial statements.

Irregularities, including fraud, are instances of non-compliance with laws and regulations. We design procedures in line with our responsibilities, outlined above, to detect material misstatements in respect of irregularities, including fraud. The extent to which our procedures are capable of detecting irregularities, including fraud is detailed below:

Based on our understanding of the charitable company and the environment in which it operates, we identified that the principal risks of non-compliance with laws and regulations related to charity and company law applicable in England and Wales, and we considered the extent to which non-compliance might have a material effect on the financial statements. We also considered those laws and regulations that have a direct impact on the preparation of the financial statements such as Companies Act 2006, fundraising regulations and the Charities Act 2011.

We evaluated management’s incentives and opportunities for fraudulent manipulation of the financial statements (including the risk of override of controls) and determined that the principal risks were related

Unlimit Health annual report and financial statements 2025-2026 | 45

to the posting of improper journals to revenue. Audit procedures performed by the engagement team included:

Because of the inherent limitations of an audit, there is a risk that we will not detect all irregularities, including those leading to a material misstatement in the financial statements or non-compliance with regulation. This risk increases the more that compliance with a law or regulation is removed from the events and transactions reflected in the financial statements, as we will be less likely to become aware of instances of non-compliance. The risk is also greater regarding irregularities occurring due to fraud rather than error, as fraud involves intentional concealment, forgery, collusion, omission, or misrepresentation.

A further description of our responsibilities for the audit of the financial statements is located on the Financial Reporting Council’s website at: www.frc.org.uk/auditorsresponsibilities. This description forms part of our auditor’s report.

Use of our report

This report is made solely to the charitable company's members, as a body, in accordance with Chapter 3 of Part 16 of the Companies Act 2006. Our audit work has been undertaken so that we might state to the charitable company's members those matters we are required to state to them in an Auditor's report and for no other purpose. To the fullest extent permitted by law, we do not accept or assume responsibility to anyone other than the charitable company and the charitable company's members, as a body, for our audit work, for this report, or for the opinions we have formed.

7th October 2026

Steven Harper (Senior Statutory Auditor)

For and on behalf of HaysMac LLP, Statutory Auditor

10 Queen Street Place London

EC4R 1AG

Unlimit Health annual report and financial statements 2025-2026 | 46

Statement of Financial Activities (incorporating income and expenditure account)

FOR THE YEAR ENDED 31 MARCH 2026

Note
INCOME FROM:
Donations and legacies
2
Charitable activities
3
Investment income
4
TOTAL INCOME
EXPENDITURE ON:
Fundraising and publicity
6
Charitable activities
6
Unrestricted
Funds
£
1,105,443
-
387,781
1,493,224
400,972
4,369,198
2026
Restricted
Funds
£
220,446
4,137,584
-
4,358,030
72,622
4,035,608
Total Funds
Year ended
31-Mar-26
£
1,325,889
4,137,584
387,781
5,851,254
473,594
8,404,806
Unrestricted
Funds
£
1,135,491
-
386,941
1,522,432
441,551
3,485,764
2025
Restricted
Total Funds
Funds
Year ended
31-Mar-25
£
£
184,223
1,319,714
5,096,944
5,096,944
-
386,941
5,281,167
6,803,599
89,029
530,580
4,800,456
8,286,220
TOTAL EXPENDITURE 4,770,170 4,108,230 8,878,400 3,927,315 4,889,485
8,816,800
NET (EXPENDITURE)/INCOME BEFORE
INVESTMENT MOVEMENTS
Gains/(losses) on investments
NET INCOME
(3,276,946)
(94,783)
(3,371,729)
249,800
-
249,800
(3,027,146)
(94,783)
(3,121,929)
(2,404,883)
63,579
(2,341,304)
391,682
(2,013,201)
-
63,579
391,682
(1,949,622)
Transfer between funds 320,578 (320,578) - 295,453 (295,453)
-
NET MOVEMENT IN FUNDS
Reconciliation of funds:
Total funds brought forward
(3,051,151)
11,806,769
(70,778)
304,596
(3,121,929)
12,111,365
(2,045,851)
13,852,620
96,229
(1,949,622)
208,367
14,060,987
TOTAL FUNDS CARRIED FORWARD 8,755,618 233,818 8,989,436 11,806,769 304,596
12,111,365

All transactions are derived from activities that commenced during the period. All recognised gains and losses are included in the Statement of Financial Activities.

Unlimit Health annual report and financial statements 2025-2026 | 47

Balance Sheet (Company Number

1177531

Unlimit Health annual report and financial statements 2025-2026 | 48

Statement of Cash Flows

FOR THE YEAR ENDED 31 MARCH 2026

Note
Cash Flow from operating activities
22
Cash flows from investing activities
Income from listed investments
Other interest receivable
£
£
£
£
(5,743,463)
(6,416,751)
366,615
348,458
21,166
38,483
2026
2025
£
£
£
£
(5,743,463)
(6,416,751)
366,615
348,458
21,166
38,483
2026
2025
Payments to acquire tangible fixed assets
(3,080)
Sale of investments
5,000,000
Cash used in investing activities
Cash and cash equivalents at the beginning of the year
Increase/(decrease) in cash and cash
equivalents in the year
(3,080) (15,183)
-
5,384,701
371,758
(358,762)
(6,044,993)
6,626,010
12,412,940
6,267,248
6,367,947
Change due to exchange rate movements
Total cash and cash equivalents at the end of the year
Cash and cash equivalents
Cash at bank and in hand
Cash at bank and in hand at the end of the
reporting period
72,193
258,063
6,339,441
6,626,010
6,339,441
6,626,010
6,339,441
6,626,010

Unlimit Health annual report and financial statements 2025-2026 | 49

Notes to the financial statements

  1. Accounting policies: The principal accounting policies adopted, judgements and key sources of estimation uncertainty in the preparation of the financial statements are as follows:

  2. a. Basis of preparation: The financial statements have been prepared in accordance with Accounting and Reporting by Charities: Statement of Recommended Practice applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102) (Second Edition, effective 1 January 2019) – (Charities SORP (FRS 102), the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102) and the Companies Act 2006.

The subsidiary was dormant in the current and previous financial year, and so current year figures are for the Charity alone.

The Charity meets the definition of a public benefit entity under FRS 102. Assets and liabilities are initially recognised at historical cost or transaction value unless otherwise stated in the relevant accounting policy note.

Preparation of the accounts as a going concern: Having reviewed the funding facilities available to the Charity together with the expected future cash flows, the trustees have a reasonable expectation that charity has adequate resources to continue its activities for the foreseeable future and consider that there were no material uncertainties identified over the Charity's financial viability. Accordingly, they also continue to adopt the going concern basis in preparing the financial statements.

Income: All income is included in the Statement of Financial Activities (SoFA) when the Charity is legally entitled to the income after any performance conditions have been met, the amount can be measured reliably, and it is probable that the income will be received. The SORP requirements are followed in relation to positions where there is a time restriction. The cost of donated drugs for the Mass Drug Administration is not included in the UH income or expenditure accounts because the drugs are donated directly to the ministries of health with which we operate. For donations to be recognised the Charity will have been notified of the amounts and the settlement date in writing. If there are conditions attached to the donation and this requires a level of performance before entitlement can be obtained, then income is deferred until those conditions are fully met or the fulfilment of those conditions is within the control of the Charity, and it is probable that they will be fulfilled.

No amount is included in the financial statements for general volunteer time in line with the SORP (FRS 102).

Investment income is earned through holding assets for investment purposes. It includes dividends and interest. It is included when the amount can be measured reliably. Interest income is recognised using

Unlimit Health annual report and financial statements 2025-2026 | 50

the effective interest method and dividend income is recognised as the Charity’s right to receive payment is established.

Designated funds comprise unrestricted funds that have been set aside by the trustees for particular purposes. The aim and use of each designated fund is set out in the notes to the financial statements. Restricted funds are funds which are to be used in accordance with specific restrictions imposed by donors, or which have been raised by the Charity for particular purposes. The cost of raising and administering such funds are charged against the specific fund. The aim and use of each restricted fund is set out in the notes to the financial statements.

Costs of raising funds includes direct staff costs, external costs such as advertising and marketing and other costs associated with attracting voluntary income. Cost of raising funds also includes investment manager fees and costs associated with attracting trading income.

Charitable activities are for improving the health of the poorest and most marginalised societies in the world through the elimination of parasitic worm infections. We do this by supporting governments in sub-Saharan African countries to develop effective and sustainable programmes against these diseases. Costs of charitable activities include costs directly associated with delivering public health interventions such as mass drug administration that support the control and elimination of parasitic worm infections and an apportionment of overhead, support, and governance costs.

Irrecoverable VAT is charged as an expense against the activity for which expenditure arose.

Unlimit Health annual report and financial statements 2025-2026 | 51

and underlying assumptions are based on historical experience and other factors that are considered to be relevant. Actual results may differ from these estimates.

The estimates and underlying assumptions are reviewed on an ongoing basis. Revisions to accounting estimates are recognised in the period in which the estimate is revised if the revision affects only that period, or in the period of the revision and future periods if the revision affected current and future periods. There are no estimates or judgements which the Trustees consider are subject to significant uncertainty.

Depreciation is provided on all tangible fixed assets, at rates calculated to write off the cost, less estimated residual value, of each asset on a systematic basis over its expected useful life as follows: Office furniture, fittings and equipment, computer equipment.

Investments in subsidiaries are measured at cost less impairment.

Unlimit Health annual report and financial statements 2025-2026 | 52

is significantly different. Monetary assets and liabilities denominated in foreign currencies at the balance sheet date are translated at the rates ruling at that date. All exchange differences are taken to the Statement of Financial Activities.

Unlimit Health annual report and financial statements 2025-2026 | 53

NOTES TO THE FINANCIAL STATEMENTS (continued)

FOR THE YEAR ENDED 31 MARCH 2026

2.
DONATIONS AND LEGACIES
Unrestricted
£
Donations
1,105,443
3.
CHARITABLE ACTIVITIES
Unrestricted
£
Grants
-
Consultancy income
-
-
4.
INVESTMENT INCOME
Unrestricted
£
Income from investments
366,615
Other interest receivable
21,166
387,781
5.
NET INCOME FOR THE YEAR
This is stated after charging the following:
- Auditors remuneration
Audit
Other services
- Operating lease rentals
2026
Restricted
£
220,446
Restricted
£
3,981,779
155,805
4,137,584
Restricted
£
-
-
-
Year ended
31-Mar-26
£
1,325,889
Year ended
31-Mar-26
£
3,981,779
155,805
4,137,584
Year ended
31-Mar-26
£
366,615
21,166
387,781
Year ended
31-Mar-26
£
26,160
8,094
29,154
Unrestricted
£
1,135,491
Unrestricted
£
-
-
-
Unrestricted
£
348,458
38,483
386,941
2025
Year ended
Restricted
31-Mar-25
£
£
184,223
1,319,714
Year ended
Restricted
31-Mar-25
£
£
5,007,749
5,007,749
89,195
89,195
5,096,944
5,096,944
Year ended
Restricted
31-Mar-25
£
£
-
348,458
-
38,483
-
386,941
Year ended
31-Mar-25
£
24,900
6,523
27,265

Unlimit Health annual report and financial statements 2025-2026 | 54

NOTES TO THE FINANCIAL STATEMENTS (continued)

FOR THE YEAR ENDED 31 MARCH 2026

6. EXPENDITURE a) ANALYSIS OF EXPENDITURE

Fundraising and publicity
Expenditure on charitable activities
TOTAL EXPENDITURE
Fundraising and publicity
Expenditure on charitable activities
TOTAL EXPENDITURE
ANALYSIS OF SUPPORT COSTS
Fundraising and publicity
Expenditure on charitable activities
TOTAL SUPPORT COSTS
Fundraising and publicity
Expenditure on charitable activities
TOTAL SUPPORT COSTS
GOVERNANCE COSTS
Legal and professional, including audit
Partner Awards
£
-
5,056,117
5,056,117
Partner Awards
£
-
5,508,285
5,508,285
Office
expenses
£
2,043
9,395
11,438
Office
expenses
£
1,635
6,456
8,091
FOR THE YE
Support Costs
£
52,985
243,525
296,510
FOR THE YE
Support Costs
£
63,050
248,947
311,997
FOR THE YE
Property
costs
£
5,689
26,144
31,833
FOR THE YE
Property
costs
£
6,169
24,362
30,531
AR ENDED 31 MARCH 2026
Staff Costs
Other Direct
Total
£
£
£
375,790
44,819
473,594
1,963,967
1,141,197
8,404,806
2,339,757
1,186,016
8,878,400
AR ENDED 31 MARCH 2025
Staff Costs
Other Direct
Total
£
£
£
402,751
64,779
530,580
1,787,379
741,609
8,286,220
2,190,130
806,388
8,816,800
AR ENDED 31 MARCH 2026
Other
support costs
Governance
costs
Total
£
£
£
38,512
6,741
52,985
177,004
30,982
243,525
215,516
37,723
296,510
AR ENDED 31 MARCH 2025
Other
support costs
Governance
costs
Total
£
£
£
48,314
6,932
63,050
190,757
27,372
248,947
239,071
34,304
311,997
Year ended
Year ended
31-Mar-26
31-Mar-25
£
£
37,723
34,304

Unlimit Health annual report and financial statements 2025-2026 | 55

NOTES TO THE FINANCIAL STATEMENTS (continued)

FOR THE YEAR ENDED 31 MARCH 2026

6. EXPENDITURE (continued)
Partner awards
Cote d'Ivoire
Programme National de Lutte contre les
Maladies Tropicales Négligées à
Chimiothérapie Préventive
Democratic Republic of Congo
United Front Against River Blindness
Ethiopia
NALA Foundation
Kenya
Kenya Red Cross Society
African Institute For Health & Development
Liberia
Effect Hope
Ministry of Health, Republic of Liberia
Madagascar
Réseau International Schistosomoses
Environment Aménagement et Lutte
3A Madagascar
Malawi
The Government of the Republic of Malawi,
Ministry of Health and Population
Kamuzu University of Health Sciences
Mauritania
The Government of The Islamic Republic of
Mauritania, Programme National de Lutte
contre les Maladies Tropicales Négligées
Niger
Ministère de la Santé Publique de la
République du Niger
Tanzania
Ministry of Public Health of the United
Republic of Tanzania-Zanzibar
National Institute for Medical Research
Public Health Laboratory Ivo de Carneri
Uganda
Vector Control Division, Biharzia and Worm
Control Programme, Ministry of Health
World Health Organization
Unrestricted
£
1,538,933
-
(4,892)
28,951
(18,373)
15,188
-
-
-
279,767
-
-
-
243,056
-
-
23,416
47,747
2026
Restricted
£
494,964
(8,605)
-
156,367
-
-
12,322
-
1,623,267
265,089
-
217,443
127,283
-
(2,924)
-
17,118
-
Year ended
31-Mar-26
£
2,033,897
(8,605)
(4,892)
185,318
(18,373)
15,188
12,322
-
1,623,267
544,856
-
217,443
127,283
243,056
(2,924)
-
40,534
47,747
5,056,117
Unrestricted
£
1,328,683
-
2,446
-
-
-
829
-
501
380
2,178
-
-
319,461
-
2,306
47,634
-
2025
Year ended
Restricted
31-Mar-25
£
£
914,598
2,243,281
563,316
563,316
10,680
13,126
7,487
7,487
-
-
-
-
-
829
28,955
28,955
1,717,127
1,717,628
-
380
-
2,178
-
-
-
-
21,805
341,266
68,897
68,897
-
2,306
471,002
518,636
-
-
2,153,793 2,902,324 1,704,418 3,803,867
5,508,285

Unlimit Health annual report and financial statements 2025-2026 | 56

NOTES TO THE FINANCIAL STATEMENTS (continued)

FOR THE YEAR ENDED 31 MARCH 2026

7.
STAFF NUMBERS AND COSTS
The average number of persons employed during the year were as follows
Raising funds
Charitable activities
Support
The aggregate payroll costs of these persons were as follows
Salaries and wages
Social security costs
Pension scheme contributions
2026
2025
No.
No.
3
4
19
17
7
8
29
29
£
£
1,913,641
1,806,453
232,056
207,419
136,907
122,180
2,282,604
2,136,052

Staff costs include a £28,857 termination payment made to a former employee in full and final settlement of employment-related matters. Insurance proceeds of £13,857 were recovered in respect of the matter, resulting in a net cost to the charity of £15,000.

Also included within staff costs is a statutory redundancy payment of £1,378 made to a former employee.

There were 14 employees whose emoluments, excluding pension contributions and employer's national insurance, were in excess of £60,000 (2025: 11).

£60,000 - £69,999
£70,000 - £79,999
£80,000 - £89,999
£90,000 - £99,999
2026
2025
No.
No.
3
4
5
1
4
6
2
-
14
11

The total employment costs of the key management personnel of the Foundation, including employer's national insurance and pension contributions, were £644,077 (2025: £604,485).

8. TRUSTEES' REMUNERATION AND REIMBURSED EXPENSES

No remuneration is paid to any trustee. Travelling expenses of £1,542 and subsistence expenses of £647 were paid on behalf of or reimbursed to trustees for attendance at trustee meetings (2025: £2,535).

9.
TANGIBLE ASSETS
Furniture Fixtures and Equipment
Cost or Valuation
At 31 March 2025
Additions
At 31 March 2026
Depreciation & Amortisation
At 31 March 2025
Charged in Year
At 31 March 2026
Net Book Value
At 31 March 2026
2026
2025
£
£
22,321
7,138
3,080
15,183
25,401
22,321
(8,288)
(5,552)
(5,207)
(2,736)
(13,495)
(8,288)
11,906
14,033

Unlimit Health annual report and financial statements 2025-2026 | 57

NOTES TO THE FINANCIAL STATEMENTS (continued)

FOR THE YEAR ENDED 31 MARCH 2026

10. INVESTMENTS
Market value at 31 March 2025
Additions
Disposals at market value
Realised profit/(loss) on disposal
Unrealised profit/(loss) on revaluation
Market value at 31 March 2026
Historical cost at 31 March 2026
2026
2025
£
£
11,405,766
11,342,187
-
-
(5,000,000)
-
(17,594)
-
(77,189)
63,579
6,310,983
11,405,766
6,205,497
11,000,000

Investments are held as income units in the COIF Charities Ethical Investment Fund and the COIF Charities Fixed Income fund managed by CCLA Fund Managers Limited. Distributions from the funds of £366,615 were received during the year (2025: £348,458).

11. INVESTMENT IN SUBSIDIARY

The Charity holds 100% of the £1 share capital of SCIF Services Limited, registered in England and Wales (company registration number 12190612). The company was dormant during the year and previous year.

12. TAXATION

Unlimit Health is a registered charity and, therefore, is not liable to income tax or corporation tax on income derived from its charitable activities, as it falls within the various exemptions available to registered charities.

13. DEBTORS
Trade debtors
Other debtors
Prepayments and accrued income
14. CREDITORS: Amounts falling due within one year
Trade creditors
Other creditors including taxation and social security
Accruals
Deferred income
15. CREDITORS: Amounts falling due after one year
Deferred income
The movements in deferred income are analysed as follows:
Brought forward deferred income
Income released in the year
Income deferred
Carried forward deferred income
2026
2025
£
£
17,465
-
8,143
9,423
474,745
423,504
500,353
432,927
2026
2025
£
£
89,928
91,003
94,649
94,804
283,334
196,660
3,705,336
2,766,101
4,173,247
3,148,568
2026
2025
£
£
-
3,218,803
2026
2025
£
£
5,984,904
9,853,830
(2,330,208)
(3,907,407)
50,640
38,481
3,705,336
5,984,904

Unlimit Health annual report and financial statements 2025-2026 | 58

NOTES TO THE FINANCIAL STATEMENTS (continued)

FOR THE YEAR ENDED 31 MARCH 2026

16. FUNDS
Unrestricted Funds
Designated Funds
General Funds
Restricted Funds
Grants (Note 24)
Unrestricted Funds
Designated Funds
General Funds
Restricted Funds
Grants
At 31 March
2025
£
4,553,972
7,252,797
11,806,769
304,596
12,111,365
At 31 March
2024
£
5,824,004
8,028,616
13,852,620
208,367
14,060,987
Income
£
-
1,493,224
1,493,224
4,358,030
5,851,254
Income
£
-
1,522,432
1,522,432
5,281,167
6,803,599
Expenditure
£
(1,860,414)
(2,909,756)
(4,770,170)
(4,108,230)
(8,878,400)
Expenditure
£
(1,270,032)
(2,657,283)
(3,927,315)
(4,889,485)
(8,816,800)
Investment
movements
£
-
(94,783)
(94,783)
-
(94,783)
Investment
movements
£
-
63,579
63,579
-
63,579
Transfers
At 31 March
2026
£
£
1,231,258
3,924,816
(910,680)
4,830,802
320,578
8,755,618
(320,578)
233,818
-
8,989,436
Transfers
At 31 March
2025
£
£
-
4,553,972
295,453
7,252,797
295,453
11,806,769
(295,453)
304,596
-
12,111,365

Designated funds have been allocated by the Board of Trustees to fund planned charitable activities over the next two financial years.

17. ANALYSIS OF FUND BALANCES BETWEEN NET ASSETS

Tangible fixed assets
Investments
Restricted
Funds
£
-
-
At 31 March 2026
General
Funds
Designated
Funds
Total
£
£
£
11,906
-
11,906
6,310,983
-
6,310,983
At 31 March 2026
General
Funds
Designated
Funds
Total
£
£
£
11,906
-
11,906
6,310,983
-
6,310,983
Net current assets 233,818 (1,492,087) 3,924,816
2,666,547
Tangible fixed assets
Investments
Net current assets
Creditors: Amounts falling due after one year
233,818
Restricted
Funds
£
-
-
304,596
-
304,596
4,830,802
3,924,816
8,989,436
At 31 March 2025
General
Funds
Designated
Funds
Total
£
£
£
14,033
-
14,033
11,405,766
-
11,405,766
(948,199)
4,553,972
3,910,369
(3,218,803)
-
(3,218,803)
7,252,797
4,553,972
12,111,365

Unlimit Health annual report and financial statements 2025-2026 | 59

NOTES TO THE FINANCIAL STATEMENTS (continued)

FOR THE YEAR ENDED 31 MARCH 2026

18. CAPITAL COMMITMENTS

At 31 March 2026, the Charity had no capital commitments contracted for but not provided in these financial statements (2025: none).

19. OPERATING LEASE COMMITMENTS

OPERATING LEASE COMMITMENTS
Within one year
In one to five years
2026
2025
Land &
Buildings
Land &
Buildings
£
£
14,586
11,576
-
-
14,586
11,576

20. MEMBERS' LIABILITY

In the event of the company being wound up, they will each have a liability of £1.

21. PENSION COMMITMENTS

Unlimit Health operates a Group pension arrangement. The overall pension charge for the year was £136,907 (2025: £122,180). At 31 March 2026, contributions of £nil were outstanding (2025: £19,991).

22. RECONCILIATION OF NET MOVEMENT IN FUNDS TO NET CASH FLOW

Net movement in funds
Investment income
(Gains)/losses on investments
Depreciation
Exchange rate (gain)/loss
Increase/(decrease) in creditors
(Increase)/decrease in debtors
Net Cash generated by operating activities
2026
2025
£
£
(3,121,929)
(1,949,622)
(387,781)
(386,941)
94,783
(63,579)
5,207
2,736
(72,193)
(258,063)
(2,194,124)
(3,712,416)
(67,426)
(48,866)
(5,743,463)
(6,416,751)

23. RELATED PARTY TRANSACTIONS

There were no related party transactions in the current or preceding accounting periods.

Unlimit Health annual report and financial statements 2025-2026 | 60

NOTES TO THE FINANCIAL STATEMENTS (continued)

FOR THE YEAR ENDED 31 MARCH 2026

24
Restricted Grants Details 2025/26*
At 31 March
2025
£**
Madagascar Drugs Distribution 2025-2026
-
Epidemiological Surveys
-
Integrated Child Health Uganda (End Fund)
-
Malawi Test Kits
-
Interruption of Transmission Analysis
-
Integrated Child Health Uganda (Merck)
-
Schistosomiasis Straegic Framework
-
Good Ventures Foundation 2022-24
-
GiveWell Foundation 2024-26
-
Paediatric PZQ Consortium GHIT
-
Paediatric PZQ Consortium EDCTP
-
Community-led action against disease
-
Malawi Reassessment
128,069
Zanzibar Appeal for under 5s
-
Preventing Parasitic Disease in Young Women
176,527
Schisto Oversampling Surveys 23-24 TFGH
-
FGS Burden Study 2023-24 TFGH
-
Niger MDA 2025 TLYCS
-
Uganda T-Sol MRC
-
Breaking Transmission Doc 2024 CIFF
-
Côte d'Ivoire Drugs Distribution 2025
-
Gap Assessment Tool WHO
-
304,596
24
Restricted Grants Details 2025/26*
At 31 March
2025
£**
Madagascar Drugs Distribution 2025-2026
-
Epidemiological Surveys
-
Integrated Child Health Uganda (End Fund)
-
Malawi Test Kits
-
Interruption of Transmission Analysis
-
Integrated Child Health Uganda (Merck)
-
Schistosomiasis Straegic Framework
-
Good Ventures Foundation 2022-24
-
GiveWell Foundation 2024-26
-
Paediatric PZQ Consortium GHIT
-
Paediatric PZQ Consortium EDCTP
-
Community-led action against disease
-
Malawi Reassessment
128,069
Zanzibar Appeal for under 5s
-
Preventing Parasitic Disease in Young Women
176,527
Schisto Oversampling Surveys 23-24 TFGH
-
FGS Burden Study 2023-24 TFGH
-
Niger MDA 2025 TLYCS
-
Uganda T-Sol MRC
-
Breaking Transmission Doc 2024 CIFF
-
Côte d'Ivoire Drugs Distribution 2025
-
Gap Assessment Tool WHO
-
304,596
Income
£
Expenditure
£
Transfers
At 31 March
2026
£
£
1,043,395 (893,559) (149,836)
-
1,096 (1,096) -
-
3,888 (3,381) (507)
-
3,280 - (3,280)
-
9,702 (9,702) -
-
8,821 (4,485) (4,336)
-
727,999 (633,325) (94,674)
-
818,062 (818,062) -
-
454,986 (387,252) (67,734)
-
21,427 (19,923) (1,504)
-
794,297 (762,163) (32,134)
-
- (1,443) 1,443
-
115,531 (309,829) 66,229
-
88,249 - -
88,249
(25,000) (5,958) -
145,569
- 10,124 (12,836) 2,712
-
- 1,049 (6,464) 5,415
-
- 133,571 (133,571) -
-
- 51,182 (55,633) 4,451
-
- 34,381 (29,224) (5,157)
-
-
-
41,666
20,324
-
(20,324)
(41,666)
-
-
-
304,596 4,358,030 (4,108,230) (320,578)
233,818
Restricted Grants Details 2024/25*
At 31 March
2024
£**
Ethiopia Reassesment
-
Madagascar drugs distribution
-
Epidemiological surveys
-
DRC Reassessment
-
Integrated Child Health Uganda (End Fund)
-
Integrated Child Health Uganda (Merck)
-
Schistosomiasis Straegic Framework
-
Good Ventures Foundation 2022-24
-
GiveWell Foundation 2024-26
Paediatric PZQ Consortium GHIT
-
Paediatric PZQ Consortium EDCTP
-
Community-led action against disease
44,597
Malawi Reassessment
-
Preventing Parasitic Disease in Young Women
154,043
Schisto Oversampling Surveys 23-24 TFGH
-
FGS Burden Study 2023-24 TFGH
-
Precision Public Health Technical Approach
9,728
Stichting Effectief Doneren re GiveWell
-
Breaking Transmission Doc 2024 CIFF
-
Zanzibar MDA 2024-25 CAF Canada
-
Gap Assessment Tool TFGH
-
208,368
Income
£
13,273
1,162,503
32,174
46,677
133,255
57,581
58,582
2,708,935
78,035
358,774
257,524
-
128,069
25,000
46,514
38,879
31,153
48,829
3,698
51,606
105
5,281,166
Expenditure
£
(73,476)
(1,261,589)
(19,234)
(42,846)
(115,874)
(50,070)
(50,941)
(2,429,609)
(67,857)
(325,490)
(237,236)
(56,214)
-
(2,516)
(40,115)
(29,803)
(40,881)
(42,517)
(3,216)
-
-
(4,889,484)
Transfers
At 31 March
2025
£
£
60,203
-
99,086
-
(12,940)
-
(3,831)
-
(17,381)
-
(7,511)
-
(7,641)
-
(279,326)
-
(10,178)
-
(33,284)
-
(20,288)
-
11,617
-
-
128,069
-
176,527
(6,399)
-
(9,076)
-
-
-
(6,312)
-
(482)
-
(51,606)
-
(105)
-
(295,454)
304,596

Funds are transferred from Unrestricted to Restricted Reserves when the expenditure on a restricted grant is greater than the cumulative grant income.

Funds are transferred from Restricted to Unrestricted Reserves when income for a grant is greater than expenditure and there are no further grant obligations to satisfy, or when grants provide for a level of unrestricted overhead contribution.

Unlimit Health annual report and financial statements 2025-2026 | 61